Meta-Analysis
Copyright ©The Author(s) 2017.
World J Gastrointest Oncol. Dec 15, 2017; 9(12): 475-491
Published online Dec 15, 2017. doi: 10.4251/wjgo.v9.i12.475
Table 1 Characteristics of the included studies
Ref.Country of originStudy typeStudy periodFemale(number, L/O)Mean age (yr, L/O)Intervention (L-CME) right/transverse/left location of the tumorControl (O-CME) right/transverse/left location of the tumorAdjuvant chemotherapy
Kim et al[23], 2016South KoreaCase control, unicentre, prospective database2008-201362/4469/67116/0/099/0/0L-CME = 68 pts (58.62%), O-CME = 78 pts (78.78%), recommended to all stage II and III
Storli et al[22], 2016NorwayProspective non RT, unicentre2007-201422/1373/230/33/00/23/0L-CME = 8 (61.5%), O-CME = 5 (62.5%), all stage III below 75 yr
Huang et al[24], 2015ChinaCase control, unicentre2012-201320/2156/5553/0/049/0/0NR
Yamamoto et al[20], 2014JapanRCT, multicentre2004-2009248/21564/64144/0/389156/0/368NR, recommended for all stage III
Munkedal et al[25], 2014DenmarkProspective nonRT, unicentre2008-201130/3869.1/72.930/0/5341/0/38NR
Bae et al[27], 2014South KoreaCase control, unicentre2006-200840/3864/6573/12/076/9/0All stage III and II with poor prognosis
Han et al[26], 2014ChinaCase control, unicentre2003-201094/6767/65177/0/0147/0/0NR, recommended for high risk stage II and stage III
Zhao et al[28], 2014ChinaCase control, multicentre2000-200953/4461.3/64.589/30/065/36/0NR, recommended for high risk stage II and stage III
Cong et al[29], 2014ChinaCase control, unicentre2008-201153/4561.5/62.396/0/082/0/0NR
Storli et al[30], 2013NorwayProspective nonRT, unicentre2007-201049/6071.9/73.150/18/60 2 pts - multiple35/44/42All stage III below 75 yr
Gouvas et al[31], 2012GreeceProspective nonRT, multicentric2006-201019/1762.1/66.37/9/339/9/23NR
Sun et al[32], 2012ChinaCase control, unicentre2000-200858/4560.1/61.949/7/9143/9/74NR, according to stage